<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03068481</url>
  </required_header>
  <id_info>
    <org_study_id>KDT1102</org_study_id>
    <nct_id>NCT03068481</nct_id>
  </id_info>
  <brief_title>A Phase I Clinical Study of KDT-3594 in Healthy Adult Males and Patients With Parkinson's Disease.</brief_title>
  <sponsors>
    <lead_sponsor>
      <agency>Kissei Pharmaceutical Co., Ltd.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Kissei Pharmaceutical Co., Ltd.</source>
  <brief_summary>
    <textblock>
      The purpose of this study in healthy adult males is to investigate safety and
      pharmacokinetics of single and multiple oral doses of KDT-3594.

      The purpose of this study in patients with Parkinson's disease is to investigate safety and
      pharmacokinetics of single and multiple oral doses of KDT-3594. The exploratory efficacy of
      KDT-3594 will also be investigated.
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <primary_completion_date type="Anticipated">January 2018</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <primary_outcome>
    <measure>Occurrence of adverse events</measure>
    <time_frame>Up to 15 days after last administration</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Plasma pharmacokinetic parameter of KDT-3594 and main metabolites: Cmax</measure>
    <time_frame>Up to 336 hours after last administration</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Plasma pharmacokinetic parameter of KDT-3594 and main metabolites: AUC</measure>
    <time_frame>Up to 336 hours after last administration</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Unified Parkinson's Disease Rating Scale (UPDRS) score (Only patient part)</measure>
    <time_frame>Up to 336 hours after last administration</time_frame>
  </secondary_outcome>
  <number_of_arms>5</number_of_arms>
  <condition>Parkinson Disease</condition>
  <arm_group>
    <arm_group_label>Healthy volunteer part -Single dose</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Single oral dose of KDT-3594</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Healthy volunteer part -Multiple dose</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Multiple oral doses of KDT-3594</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Healthy volunteer part -Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Multiple oral doses of Placebo</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Patient part -Single dose</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Single oral dose of KDT-3594</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Patient part -Multiple dose</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Multiple oral doses of KDT-3594</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>KDT-3594</intervention_name>
    <arm_group_label>Healthy volunteer part -Single dose</arm_group_label>
    <arm_group_label>Healthy volunteer part -Multiple dose</arm_group_label>
    <arm_group_label>Patient part -Single dose</arm_group_label>
    <arm_group_label>Patient part -Multiple dose</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <arm_group_label>Healthy volunteer part -Placebo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Healthy volunteer part

               -  Healthy Japanese males aged 20 to 35 years, inclusive

          -  Patient part

               -  Patients who are diagnosed with Parkinson's disease according to UK Parkinson's
                  Disease society brain bank clinical diagnostic criteria

               -  Patients with Parkinson's disease in Stages 1 to 3 on the Modified Hoehn and Yahr
                  Scale

               -  Male patients with Parkinson's disease aged 20 to 74 years inclusive,
                  post-menopausal female patients with Parkinson's disease aged 50 to 74 years
                  inclusive

        Exclusion Criteria:

          -  Healthy volunteer part

               -  Subjects with any abnormal findings in physical examination vital signs, 12-lead
                  ECG, clinical laboratory tests, ophthalmic examinations and
                  electroencephalography

          -  Patient part

               -  Patients who are suspected any parkinsonism except for idiopathic Parkinson's
                  disease

          -  Healthy volunteer part and patient part

               -  Subjects who do not agree to avoid dangerous works such as driving, mechanical
                  operation and high-place work until completion of the follow-up examination
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>20 Years</minimum_age>
    <maximum_age>74 Years</maximum_age>
  </eligibility>
  <overall_contact>
    <last_name>Kissei Pharmaceutical Co., Ltd</last_name>
    <email>rinsyousiken@pharm.kissei.co.jp</email>
  </overall_contact>
  <location>
    <facility>
      <address>
        <city>Kyushu and Other regions</city>
        <country>Japan</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location_countries>
    <country>Japan</country>
  </location_countries>
  <verification_date>February 2017</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>February 26, 2017</study_first_submitted>
  <study_first_submitted_qc>February 26, 2017</study_first_submitted_qc>
  <study_first_posted type="Actual">March 1, 2017</study_first_posted>
  <last_update_submitted>February 26, 2017</last_update_submitted>
  <last_update_submitted_qc>February 26, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">March 1, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Parkinson Disease</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

